BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

Search

Fresenius SE & Co KGaA

Fermé

SecteurSoins de santé

39.86 -0.2

Résumé

Variation du prix de l'action

24h

Actuel

Min

39.7

Max

40.25

Chiffres clés

By Trading Economics

Revenu

-48M

271M

Ventes

264M

5.6B

P/E

Moyenne du Secteur

24.381

57.333

Marge bénéficiaire

4.813

Employés

176,486

EBITDA

-33M

724M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+17.39% upside

Dividendes

By Dow Jones

Prochains Résultats

7 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

1.1B

22B

Ouverture précédente

40.06

Clôture précédente

39.86

Score Technique

By Trading Central

Confiance

Bullish Evidence

Fresenius SE & Co KGaA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

26 févr. 2025, 13:37 UTC

Market Talk

European Stocks on Track for Record Close as Earnings Lift Mood -- Market Talk

5 juin 2024, 12:18 UTC

Market Talk

Fresenius Helios Guidance Lift Should Drive Consensus Upgrades -- Market Talk

Comparaison

Variation de prix

Fresenius SE & Co KGaA prévision

Objectif de Prix

By TipRanks

17.39% hausse

Prévisions sur 12 Mois

Moyen 46.78 EUR  17.39%

Haut 56.9 EUR

Bas 42 EUR

Basé sur 13 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

13 ratings

11

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

39.5 / 39.92Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Weak Bearish Evidence

Long Terme

Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Fresenius SE & Co KGaA

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.